BioDelivery Sciences pain drug fails late: stage study

March 30, 2015 12:04 PM

7 0

(Reuters) - BioDelivery Sciences International Inc said its pain drug failed to meet the main goal of a late-stage study, sending the drugmaker's shares down nearly 30 percent premarket.

The Clonidine topical gel was not effective against a placebo in treating painful diabetic neuropathy, BioDelivery said in a statement on Monday.

Also read: Packers' Mason Crosby sets record with 2 late 50-yard field goals

Read more

To category page